All Stories

  1. Association between COVID-19 outcomes and mask mandates, adherence, and attitudes
  2. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
  3. Comparison of Incidence and Outcomes of Cardiogenic Shock Complicating Posterior (Inferior) Versus Anterior ST-elevation Myocardial Infarction
  4. Does Interleukin-17A Blockade Have a Potential Clinical Role to Reduce Cardiovascular Risk in Psoriasis?
  5. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
  6. Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Per...
  7. Strict versus Lenient versus Poor Rate Control Among Patients with Atrial Fibrillation and Heart Failure (From the Get With The Guidelines – Heart Failure Program)
  8. Minding the Gaps in Post-Myocardial Infarction Mortality Between Sweden and the UK
  9. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
  10. THEMIS and THEMIS-PCI
  11. Ticagrelor in Patients with Stable Coronary Disease and Diabetes
  12. Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes
  13. Hospital distance, socioeconomic status, and timely treatment of ischemic stroke
  14. Efficacy and Safety with Ticagrelor in Patients with Prior Myocardial Infarction in the Approved European label: Insights from PEGASUS-TIMI 54
  15. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
  16. Meta‐analysis of optimal timing of coronary intervention in non‐ST‐elevation acute coronary syndrome
  17. Targeting RNA to lower triglycerides: long strides from short molecules
  18. Thrombolysis in young adults with stroke
  19. REDUCE-IT
  20. The impact of randomized trial results on abdominal aortic aneurysm repair rates from 2003 to 2016: A population-based time-series analysis
  21. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
  22. One to 10-Day Versus 11–30-Day All-Cause Readmission and Mortality in Older Patients with Heart Failure
  23. Meta-analysis of percutaneous coronary intervention versus medical therapy in the treatment of coronary chronic total occlusion
  24. Outcomes and Resource Utilization for Non-Elective Versus Elective Transcatheter Mitral Valve Repair
  25. Rationale, Design, and Baseline Characteristics of THEMIS: Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study
  26. Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the Systolic Blood Pressure Intervention Trial (SPRINT)
  27. Relation of Concomitant Heart Failure to Outcomes in Patients Hospitalized with Influenza
  28. Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials
  29. Prevalence, Presentation, and Associated Conditions of Patients with Fibromuscular Dysplasia
  30. Relation of Admission Blood Pressure to In-hospital and 90-Day Outcomes in Patients Presenting with Transient Ischemic Attack
  31. Pulse Pressure, Cardiovascular Events, and Intensive Blood Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT)
  32. Trends in Utilization of Surgical and Transcatheter Mitral Valve Repair in the United States
  33. OUP accepted manuscript
  34. OUP accepted manuscript
  35. OUP accepted manuscript
  36. Bioresorbable vascular scaffolds in acute myocardial infarction: non-inferior or not enough data?
  37. Toward Precision Policy — The Case of Cardiovascular Care
  38. Glycated Hemoglobin and Outcomes of Heart Failure (Get-With-The-Guidelines–Heart Failure)
  39. De-Escalation of Antiplatelet Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials
  40. Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for Coronary-Artery Bypass
  41. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
  42. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
  43. Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
  44. Conditions and Factors Associated with Spontaneous Coronary Artery Dissection (From a National Population-Based Cohort Study)
  45. Meta-analysis Comparing Culprit Vessel Only Versus Multi-Vessel Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction and Cardiogenic Shock
  46. Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta-analysis
  47. Meta-analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity
  48. Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome Among Patients with History of Congestive Heart Failure (From the ATLAS-ACS-2 TIMI-51 Trial)
  49. Meta-Analysis Evaluating the Effect of Left Coronary Dominance on Outcomes After Percutaneous Coronary Intervention
  50. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients with Diabetes Mellitus (From the SAVOR-TIMI 53 Trial)
  51. Comparison of Outcomes of Transfemoral versus Transapical Approach for Transcatheter Aortic Valve Implantation
  52. Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate
  53. Trends in Incidence, Characteristics, and In-Hospital Outcomes of Patients Presenting with Spontaneous Coronary Artery Dissection (From a National Population-Based Cohort Study Between 2004 and 2015)
  54. Outcomes of Patients Receiving Downstream Revascularization after Initial Medical Management for Non–ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial)
  55. The Reply
  56. Subclinical Leaflet Thrombosis and Clinical Outcomes after TAVR: A Systematic Review and Meta-Analysis
  57. Electronic Health Records and Outpatient Cardiovascular Disease Care Delivery: Insights from the American College of Cardiology’s PINNACLE India Quality Improvement Program (PIQIP)
  58. Segmental Arterial Mediolysis: an Important but Often Overlooked Cause of Multi-Vessel Thrombosis
  59. Diabetes Mellitus and Cardiogenic Shock Complicating Acute Myocardial Infarction
  60. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine
  61. DECLARE-TIMI 58: Participants’ baseline characteristics
  62. FFR-guided multivessel stenting reduces urgent revascularization compared with infarct-related artery only stenting in ST-elevation myocardial infarction: A meta-analysis of randomized controlled trials
  63. Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT
  64. Device Therapies
  65. Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials
  66. Regional Variation in Utilization, In-hospital Mortality, and Health-Care Resource Use of Transcatheter Aortic Valve Implantation in the United States
  67. Meta-Analysis of Aspirin Versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting
  68. Relationship of Hospital Teaching Status with in-Hospital Outcomes for ST-Segment Elevation Myocardial Infarction
  69. Comparison of Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Chronic Kidney Disease
  70. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum
  71. Clinical or Symptomatic Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Insights from the U.S. FDA MAUDE Database
  72. Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis
  73. Prognostic implications of fasting plasma glucose in subjects with echocardiographic abnormalities
  74. Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis
  75. Comparison of Outcome of Hospital Presentation ST-Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention during Off-Hours Versus on-Hours
  76. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events
  77. Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines–Coronary Artery Disease (GWTG-CAD) program
  78. Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction
  79. Temporal Trends, Complications, and Predictors of Outcomes Among Nonagenarians Undergoing Percutaneous Coronary Intervention
  80. Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke
  81. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event
  82. How I utilize laboratory monitoring of antiplatelet therapies
  83. Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes
  84. Practical considerations for cangrelor use in patients with acute coronary syndromes
  85. My Approach to the Patient With CAD and Aspirin Resistance
  86. The coronary heart team
  87. Reply
  88. First-Generation Bioresorbable Vascular Scaffolds
  89. VESS02. Effect of Operator Specialty on the Outcomes of Carotid Artery Revascularization
  90. Meta-analysis of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Left Main Coronary Artery Disease
  91. Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysis
  92. Reply
  93. High Screen Failure Rate in Patients With Resistant Hypertension: Findings From SYMPLICITY HTN-3
  94. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention
  95. Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events
  96. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry
  97. Assessment of Stable Coronary Lesions
  98. Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement
  99. Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem
  100. Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials
  101. Blood Pressure Management in Patients with Diabetes: Insights From the Diabetes Mellitus Status in Canada Survey
  102. Usefulness of Intracoronary Brachytherapy for Patients With Resistant Drug-Eluting Stent Restenosis
  103. Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention
  104. Time-honored treatments for the initial management of acute coronary syndromes: Challenging the status quo
  105. Long-term Outcomes of Carotid Endarterectomy Versus Stenting in a Multicenter Population-based Canadian Study
  106. The Management of Antiplatelet and Antithrombotic Regimens in Patients With Mechanical Valves Undergoing Percutaneous Coronary Intervention
  107. Overview of Coronary Heart Disease Risk Initiatives in South Asia
  108. Letter by Taqueti and Bhatt Regarding Article, “Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study”
  109. Sex and Age Interactions and Differences in Outcomes After Intracerebral Hemorrhage
  110. Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction
  111. Chronic Total Occlusion Percutaneous Coronary Intervention
  112. Coronary CTA in the Evaluation of Stable Chest Pain
  113. Blood pressure and cardiovascular outcomes: a closer look – Authors' reply
  114. Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria
  115. Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes—Reply
  116. A heart within a heart
  117. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk
  118. Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study
  119. Trends in Palliative Care Use in Elderly Men and Women With Severe Heart Failure in the United States—Reply
  120. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial
  121. Out With the Old Rule-Out
  122. RISK STRATIFICATION WITH THE TIMI RISK SCORE FOR SECONDARY PREVENTION AMONG PATIENTS WITH DIABETES AND ELEVATED CARDIOVASCULAR RISK
  123. HIGH-SENSITIVITY TROPONIN-T, LEFT VENTRICULAR SIZE AND FUNCTION, AND LONG-TERM OUTCOMES IN CLINICALLY STABLE, APPARENTLY HEALTHY OLDER SUBJECTS
  124. TYPE 2 MYOCARDIAL INFARCTION IN YOUNG PATIENTS PORTENDS A WORSE LONG-TERM SURVIVAL
  125. NT-PROBNP, LEFT VENTRICULAR STRUCTURE AND FUNCTION, AND LONG-TERM CARDIOVASCULAR EVENTS: INSIGHTS FROM A PROSPECTIVE POPULATION-BASED COHORT STUDY
  126. LIPID ABNORMALITIES IN YOUNG PATIENTS WITH MYOCARDIAL INFARCTION
  127. ISCHEMIC EVENTS OCCUR EARLY IN PATIENTS UNDERGOING PCI AND ARE REDUCED WITH CANGRELOR: FINDINGS FROM CHAMPION PHOENIX
  128. LEFT VENTRICULAR HYPERTROPHY AND SUBSEQUENT CARDIOVASCULAR RISK: DOES IT MATTER HOW IT IS DIAGNOSED?
  129. EFFECT OF AN ONLINE CONTINUING MEDICAL EDUCATION AND CLINICIAN COACHING QUALITY IMPROVEMENT INITIATIVE ON ANTIPLATELET MEDICATION ADHERENCE AND HOSPITAL READMISSIONS IN PATIENTS WITH ACUTE CORONARY SYNDROME
  130. ROLE OF HOSPITAL VOLUME IN IDENTIFYING LOW AND HIGH-PERFORMING SURGICAL VALVE CENTERS IN THE UNITED STATES
  131. Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients
  132. CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF UNFRACTIONATED HEPARIN – INSIGHTS FROM CHAMPION PHOENIX
  133. HYDROPHILIC VERSUS LIPOPHILIC STATINS IN CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
  134. THIRTY-DAY READMISSION RATE AND COST AFTER PERCUTANEOUS CORONARY INTERVENTION IN THE UNITED STATES: A NATIONAL READMISSION DATABASE ANALYSIS
  135. IMPACT OF FLOW, GRADIENT, AND LEFT VENTRICULAR FUNCTION ON OUTCOMES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
  136. BLOOD PRESSURE, SUBCLINICAL MYOCARDIAL INJURY AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH DIABETES AND HIGH CARDIOVASCULAR RISK: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
  137. IMPACT OF PERIPROCEDURAL MYOCARDIAL INFARCTION IN CONTEMPORARY PCI: POOLED PATIENT-LEVEL DATA FROM THE CHAMPION TRIALS
  138. Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease
  139. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis
  140. Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke
  141. New-Generation Coronary Stents: Current Data and Future Directions
  142. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
  143. Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure
  144. Healthcare Resource Availability, Quality of Care, and Acute Ischemic Stroke Outcomes
  145. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus
  146. Complete or Culprit-Only Revascularization for Patients With Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
  147. Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
  148. The Wrong Toothpaste and the Painful Burp
  149. Outcomes and Temporal Trends of Inpatient Percutaneous Coronary Intervention at Centers With and Without On-site Cardiac Surgery in the United States
  150. Cangrelor Use Since FDA Approval
  151. Combined Drugs and Procedure Trials
  152. A 24-Month Interventional Cardiology Fellowship
  153. Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations
  154. Leaflet Thrombosis in Surgically Explanted or Post-Mortem TAVR Valves
  155. Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction
  156. Differences in Acute Ischemic Stroke Quality of Care and Outcomes by Primary Stroke Center Certification Organization
  157. Transthoracic Echocardiography to Assess Aortic Regurgitation after TAVR: A Comparison with Periprocedural Transesophageal Echocardiography
  158. Structural Heart Interventional Training
  159. Subclinical bioprosthetic aortic valve thrombosis
  160. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines–Heart Failure registry
  161. Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale
  162. Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting
  163. O PIONEERs!
  164. Erratum to: Optimizing the Use of Cangrelor in the Real World
  165. Long-term Outcomes of Carotid Endarterectomy Versus Stenting: A 12-Year Multicenter Observational Analysis of 14,464 Patients
  166. Regression to the Mean in SYMPLICITY HTN-3
  167. TCT-334 Predictors of Outcomes Among Nonagenarians Undergoing Percutaneous Coronary Intervention: A National Veterans Affairs Database Study
  168. TCT-380 Outcomes of Patients with Acute Myocardial Infarction in Moderate to Severe Chronic Kidney Disease in the United States
  169. TCT-23 Contemporary Trends in Utilization of Mechanical Circulatory Support in Patients Hospitalized After Out-of-Hospital Cardiac Arrest
  170. TCT-655 High Prevalence of TAVR Leaflet Thrombosis in a Single Center Pathological Review
  171. Trends and Outcomes of Coronary Angiography and Percutaneous Coronary Intervention After Out-of-Hospital Cardiac Arrest Associated With Ventricular Fibrillation or Pulseless Ventricular Tachycardia
  172. Radial access in patients with acute coronary syndrome without persistent ST-segment elevation: Systematic review, collaborative meta-analysis, and meta-regression
  173. TCT-382 Temporal Trends in Incidence and Outcomes of Acute Kidney Injury Complicating Peripheral Vascular Interventions in the United States
  174. TCT-845 Regional Differences in the Incidence and Outcomes of Hospitalization after Out-of-Hospital Cardiac Arrest in the United States
  175. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
  176. Response by Bagai et al to Letter Regarding Article, “Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention”
  177. Effect of diastolic dysfunction on postoperative outcomes after cardiovascular surgery: A systematic review and meta-analysis
  178. Troponin and the J-Curve of Diastolic Blood Pressure
  179. Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks
  180. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study
  181. Optimizing the Use of Cangrelor in the Real World
  182. Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents
  183. Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health: A Scientific Statement From the American Heart Association
  184. Why are acute ischemic stroke patients not receiving IV tPA?
  185. Ticagrelor for patients with acute coronary syndromes: PLATOnic affair or lasting SWEDEHEART?
  186. Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry
  187. Bridging Experience With Eptifibatide After Stent Implantation
  188. OS 07-02 DIFFERENCES IN CIRCADIAN BLOOD PRESSURE VARIABILITY PATTERNS BETWEEN JAPANESE AND AMERICAN TREATMENT-RESISTANT HYPERTENSIVE POPULATIONS
  189. Relation of Obesity to Survival After In-Hospital Cardiac Arrest
  190. Heart failure medications prescribed at discharge for patients with left ventricular assist devices
  191. Do Acute Myocardial Infarction and Heart Failure Readmissions Flagged as Potentially Preventable by the 3M Potentially Preventable Readmissions Software Have More Process-of-Care Problems?
  192. Gastroprotection with proton-pump inhibitors in high-risk cardiovascular patients: who to target and for how long?
  193. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrilla
  194. Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age
  195. Concurrent Lower Gastrointestinal Bleeding Risk and Myocardial Ischemic Risk: Resume Aspirin or Not?
  196. Optimal timing of invasive management in patients with non-ST-elevation acute coronary syndromes
  197. Trends in Palliative Care Use in Veterans With Severe Heart Failure Using a Large National Cohort
  198. The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure
  199. Sex Differences in Cardiac Troponin and the Risk of Death or Major Cardiovascular Events
  200. Reply
  201. Reply
  202. Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure
  203. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry
  204. Ruminations About Renal Denervation
  205. Response by Alexander et al to Letters Regarding Article, “A Shocking Development in a Young Male Athlete With Chest Pain”
  206. Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke
  207. Adaptive Designs for Clinical Trials
  208. Allograft Vasculopathy
  209. Editorial Commentary: Bringing precision medicine to intervention: Virtually a reality
  210. Reply
  211. Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney DiseaseCLINICAL PERSPECTIVE
  212. Frequency and Implications of Ischemia Prior to Ventricular Tachyarrhythmia in Patients Treated With a Wearable Cardioverter Defibrillator Following Myocardial Infarction
  213. Highlights from the 65th American College of Cardiology Annual Scientific Session (ACC 2016)
  214. Fractional Flow Reserve in Serial Coronary Artery Stenoses
  215. Outcomes with bioabsorbable vascular scaffolds versus everolimus eluting stents
  216. Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention
  217. Bulging at the Root: An Inflammatory Tale
  218. Future prospects for renal artery denervation
  219. Reply
  220. Hospital Variation in Premature Clopidogrel Discontinuation After Drug‐Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System
  221. Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure
  222. Mechanical Thrombectomy and Functional Outcomes After Stroke
  223. Elevated Troponin Levels in Stable Patients Undergoing Hemodialysis: A Red Flag or a Red Herring?
  224. Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease
  225. TRENDS IN BLEEDING RELATED COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING CORONARY INTERVENTION FOR ACUTE MYOCARDIAL INFARCTION
  226. DOES THE SMOKER'S PARADOX EXIST IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION?
  227. IMPACT OF PRIOR CEREBROVASCULAR EVENTS ON ISCHEMIC AND BLEEDING OUTCOMES WITH CANGRELOR IN PERCUTANEOUS CORONARY INTERVENTION
  228. COST IMPLICATIONS OF PROCEDURAL THROMBOTIC COMPLICATIONS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: RESULTS FROM THE CHAMPION PHOENIX ECONOMICS STUDY
  229. MANAGEMENT AND OUTCOMES OF ST-ELEVATION MYOCARDIAL INFARCTION IN RENAL TRANSPLANT RECIPIENTS VERSUS END-STAGE RENAL DISEASE PATIENTS ON DIALYSIS
  230. SUCCESS OF MEDICAL EDUCATION ON ACS MANAGEMENT: FOCUS ON ADHERENCE TO ANTIPLATELET THERAPY POST-DISCHARGE AND REDUCING HOSPITAL READMISSIONS
  231. TEMPORAL TRENDS IN UTILIZATION OF FRACTIONAL FLOW RESERVE FOR PATIENTS WITH STABLE CORONARY ARTERY DISEASE IN THE UNITED STATES
  232. EFFICACY AND SAFETY OF TICAGRELOR AS LONG-TERM SECONDARY PREVENTION IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION AND PERIPHERAL ARTERY DISEASE
  233. HOSPITAL-LEVEL VARIATION IN THE USE OF EARLY CATHETERIZATION FOR PATIENTS WITH NON-ST ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE NCDR ACTION REGISTRY-GWTG
  234. REDUCTION IN ISCHEMIC EVENTS WITH TICAGRELOR IN DIABETIC PATIENTS FROM THE PEGASUS-TIMI 54 TRIAL
  235. ASSOCIATION OF HOSPITAL TEACHING STATUS WITH IN-HOSPITAL MORTALITY OF ST-ELEVATION MYOCARDIAL INFARCTION
  236. PATTERNS OF ASPIRIN UTILIZATION AND OUTCOMES AMONG PATIENTS WITH DIABETES MELLITUS: A PROPENSITY SCORE MATCHED ANALYSIS FROM THE SAVOR-TIMI 53 TRIAL
  237. CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL
  238. Heart failure event definitions in drug trials in patients with type 2 diabetes
  239. On the use of propensity scores in case of rare exposure
  240. Distinct Short-Term Outcomes in Patients With Mild Versus Rapidly Improving Stroke Not Treated With Thrombolytics
  241. Current status of data on cangrelor
  242. Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease
  243. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c
  244. Simultaneous Platelet P2Y12and P2Y1ADP Receptor Blockade
  245. A Shocking Development in a Young Male Athlete With Chest Pain
  246. Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction
  247. Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis
  248. Femoropopliteal Artery Stent Thrombosis
  249. Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding
  250. Bariatric surgery versus non-surgical treatment for obesity
  251. The Efficacy and Safety of Cangrelor in Women Versus Men During PCI: Insights From the CHAMPION PHOENIX Trial
  252. Percutaneous Coronary Intervention
  253. Anticoagulation for Atrial Fibrillation in the Emergency Department or Observation Unit
  254. Relation Between Hospital Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes (from the American Heart Association's Get With the Guidelines—Coronary Artery Disease Data Set)
  255. Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart FailureCLINICAL PERSPECTIVE
  256. Quantifying the 3 Biases That Lead to Unintentional Overestimation of the Blood Pressure–Lowering Effect of Renal Denervation
  257. Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension – Insights From the SYMPLICITY HTN-3 Trial –
  258. Cardiovascular health awareness and the effect of an educational intervention on school-aged children in a rural district of India
  259. Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes in Patients With Heart Failure
  260. Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus
  261. Mechanical Thrombectomy for Acute Ischemic Stroke
  262. Complete Heart Block Complicating ST-Segment Elevation Myocardial Infarction
  263. How to Decipher OCT After PCI∗
  264. Culprit-Only vs. Complete Revascularization During ST-Segment Elevation Myocardial Infarction
  265. ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise
  266. Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy
  267. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure
  268. Revisiting the Clopidogrel–Proton Pump Inhibitor Interaction
  269. Moving Toward Global Primordial Prevention in Cardiovascular Disease
  270. Distal and Tributary Targets
  271. Smoking Paradox in Patients Hospitalized With Coronary Artery Disease or Acute Ischemic Stroke
  272. TCT-83 Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 Randomized Controlled Trial
  273. TCT-7 Trends and outcomes of percutaneous coronary intervention for ventricular tachycardia or fibrillation cardiac arrest: analysis from nationwide inpatient sample
  274. TCT-227 Is aspiration thrombectomy beneficial in patients undergoing primary percutaneous coronary intervention? An updated meta-analysis of randomized trials
  275. Response to Letter Regarding Article, “Is Aspiration Thrombectomy Beneficial in Patients Undergoing Primary Percutaneous Coronary Intervention? Meta-Analysis of Randomized Trials”
  276. Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels
  277. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
  278. Aspirin and proton-pump inhibitors: interpreting the interplay
  279. TAVR in patients with severe aortic stenosis and less than high risk: Future or present reality?
  280. Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
  281. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes
  282. Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis
  283. Trends in the Use of Guideline-based Therapies Among Dialysis Patients Hospitalized with Heart Failure: Findings from Get With The Guidelines-Heart Failure
  284. Temporal Trends of Digoxin Use in Patients Hospitalized with Heart Failure: Analysis From the American Heart Association Get With The Guidelines - Heart Failure Registry
  285. Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation
  286. Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure
  287. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure
  288. Reply: Warfarin in patients on haemodialysis with atrial fibrillation—friend or foe?
  289. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap
  290. Is Aspiration Thrombectomy Beneficial in Patients Undergoing Primary Percutaneous Coronary Intervention?
  291. Manual Thrombectomy in Myocardial Infarction: Aspiring for Better
  292. Antiplatelet therapy: Defining the optimal duration of DAPT after PCI with DES
  293. Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack
  294. Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States
  295. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
  296. Accurate Conductance-Based Post-Dilation Balloon Catheter Sizing
  297. Late breaking trials of 2014 in coronary artery disease: Commentary covering ACC, EuroPCR, SCAI, TCT, ESC, and AHA
  298. Interventional and Device Therapy in Heart Failure
  299. Expanding the Boundaries of Heart Failure Care with Interventional and Device Therapy
  300. When Is a Double Better Than a TRIPLE?
  301. Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease
  302. Outcomes in Mild Acute Ischemic Stroke Treated With Intravenous Thrombolysis
  303. Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel
  304. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction
  305. Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
  306. Reply
  307. The Reply
  308. ABNORMAL STRESS ANKLE BRACHIAL INDEX PREDICTS ALL-CAUSE MORTALITY
  309. Do We Really Know the CvLPRIT in Myocardial Infarction? Or Just Stent All Lesions?∗
  310. Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin
  311. CANGRELOR IN ELDERLY PATIENTS UNDERGOING PCI: FINDINGS FROM CHAMPION-PHOENIX
  312. SEASONAL, REGIONAL, AND CIRCADIAN VARIATIONS OF ACUTE MYOCARDIAL INFARCTION: FINDINGS FROM THE GET WITH THE GUIDELINES- CORONARY ARTERY DISEASE (GWTG-CAD) PROGRAM
  313. ANTI-HYPERGLYCEMIC MEDICATION USE AMONG MEDICARE BENEFICIARIES WITH HEART FAILURE, DIABETES, AND CHRONIC KIDNEY DISEASE
  314. SOCIOECONOMIC DISPARITIES AND QUALITY OF IN-HOSPITAL CARE AFTER MYOCARDIAL INFARCTION IN THE NATIONAL CARDIOVASCULAR DATA REGISTRY
  315. RISK STRATIFICATION FOR CARDIOVASCULAR EVENTS IN THE IMPROVE-IT TRIAL
  316. TEMPORAL TRENDS IN CARDIAC REHABILITATION REFERRAL AMONG PATIENTS HOSPITALIZED WITH HEART FAILURE: ANALYSIS FROM AMERICAN HEART ASSOCIATION GET WITH THE GUIDELINES-HEART FAILURE REGISTRY
  317. STATIN INTENSITY AND OUTCOME IN PATIENTS WITH PERIPHERAL ARTERY DISEASE: INSIGHTS FROM THE TRA2P-TIMI 50 TRIAL
  318. Effect of Bariatric Surgery Versus Intensive Medical Management on Diabetic Ophthalmic Outcomes
  319. Anticoagulation therapy: Balancing the risks of stroke and bleeding in CKD
  320. Percutaneous Circulatory Assist Devices for High-Risk Coronary Intervention
  321. New Approaches to Inhibiting Platelets and Coagulation
  322. Targeted versus standard feedback: Results from a Randomized Quality Improvement Trial
  323. Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study
  324. Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure?∗
  325. Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction
  326. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population
  327. Renal Artery Revascularization
  328. Appraisal of the Clinical Trial Data on Renal Denervation for the Management of Resistant Hypertension
  329. Commentary on highlighted late breaking trials in interventional cardiology at ESC, VIVA, TCT, and AHA 2013
  330. Hospitalized Hemorrhagic Stroke Patients with Renal Insufficiency: Clinical Characteristics, Care Patterns, and Outcomes
  331. Non-adherence to cardiovascular medications
  332. Current quality of cardiovascular prevention for Million Hearts: An analysis of 147,038 outpatients from The Guideline Advantage
  333. Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: Insights from the Veterans Affairs CART Program
  334. Conductance sizing balloon for measurement of peripheral artery minimal stent area
  335. TCT-405 SYMPLICITY HTN-3: Outcomes in the African-American and non-African American Populations
  336. Association of Severe Obstructive Sleep Apnea and Elevated Blood Pressure Despite Antihypertensive Medication Use
  337. New Section Launched inClinical Cardiology!
  338. Lack of Negative Interaction Between Use of Beta-Blockers and Statins on Cardiovascular Outcomes Among Patients With or At Risk for Atherothrombosis
  339. Drug Delivering Technology for Endovascular Management of Infrainguinal Peripheral Artery Disease
  340. Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
  341. Ambulatory blood pressure results of symplicity HTN-3 trial
  342. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials
  343. Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy
  344. CPAP versus Oxygen in Obstructive Sleep Apnea
  345. Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin
  346. Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction
  347. PS126. Vascular Surgeons Can Improve the Cardiovascular Health of Patients With Clinical Atherosclerotic Cardiovascular Disease by Implementing an Intensive Lipid-Lowering Regimen and Providing Smoke Cessation Counseling
  348. Aspiration thrombectomy in patients undergoing primary angioplasty: Totality of data to 2013
  349. Balancing the risks of stent thrombosis and major bleeding during primary percutaneous coronary intervention
  350. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
  351. Reply
  352. Interaction between diabetes and a high ankle–brachial index on mortality risk
  353. Embolic Protection Devices
  354. Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative
  355. Commentary on late breaking trials in interventional cardiology at ESC, VIVA, TCT, AHA (Fall 2012), and ACC 2013
  356. Dual Antiplatelet Therapy After Stent Implantation—Reply
  357. Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction
  358. CARDIOVASCULAR EVENT RATES IN PATIENTS WITH DIABETES: INSIGHTS FROM THE INTERNATIONAL REACH REGISTRY
  359. CHARACTERISTICS, TREATMENTS, AND OUTCOMES OF HOSPITALIZED HEART FAILURE PATIENTS STRATIFIED BY ETIOLOGIES OF NON-ISCHEMIC CARDIOMYOPATHY
  360. TEMPORAL TRENDS IN EARLY FOLLOW-UP AFTER HOSPITALIZATION FOR HEART FAILURE: DATA FROM GET WITH THE GUIDELINES-HEART FAILURE
  361. SHORT- AND LONG-TERM REHOSPITALIZATION AND MORTALITY FOR HEART FAILURE IN FOUR RACIAL/ETHNIC POPULATIONS
  362. POST-DISCHARGE MORTALITY AND READMISSION IN HEART FAILURE PATIENTS WITH PRESERVED, BORDERLINE, AND REDUCED LEFT VENTRICULAR EJECTION FRACTION
  363. IMPACT OF TREATMENT MODALITIES ON HEALTH STATUS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA
  364. BASELINE RENAL FUNCTION AND CARDIOVASCULAR RISK IN PATIENTS TREATED WITH SAXAGLIPTIN: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
  365. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure
  366. Authors' Reply
  367. Hospital patterns of medical management strategy use for patients with non–ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease
  368. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: Mechanisms and solutions
  369. Impact of Smoking on Long-Term Outcomes in Patients With Atherosclerotic Vascular Disease Treated With Aspirin or Clopidogrel
  370. Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis
  371. Obstructive sleep apnea and diurnal nondipping hemodynamic indices in patients at increased cardiovascular risk
  372. Variations in Coronary Artery Disease Secondary Prevention Prescriptions Among Outpatient Cardiology Practices
  373. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry
  374. NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease
  375. Percutaneous coronary intervention in the patient on oral anticoagulation
  376. Patient and Hospital Characteristics Associated With Inappropriate Percutaneous Coronary Interventions
  377. The Impact of Lost Therapeutic Benefit (LTB) in High‐Risk Hypertensive Patients: 2‐Year Follow‐Up Data from the Australian REACH Registry
  378. Evolving Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Results From a Survey Among US Cardiologists
  379. Renal Denervation Therapy for Hypertension
  380. Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients
  381. Catheter-Based Renal Denervation
  382. Role of Aspiration and Mechanical Thrombectomy in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty
  383. TCT-471 Relation of Stent Thrombosis to Interruption of Dual Antiplatelet Therapy After Resolute Zotarolimus-eluting Stent Implantation
  384. Outcomes and Excess Costs among Patients with Cardiovascular Disease
  385. CT-based Diagnosis of Diffuse Coronary Artery Disease on the Basis of Scaling Power Laws
  386. Statin potency associated with incident diabetes in a real-world evaluation
  387. Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis
  388. What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?
  389. Risk-Standardizing Survival for In-Hospital Cardiac Arrest to Facilitate Hospital Comparisons
  390. Racial/Ethnic Differences in B-Type Natriuretic Peptide Levels and Their Association With Care and Outcomes Among Patients Hospitalized With Heart Failure
  391. Socioeconomic Disparities in the Use of Cardioprotective Medications Among Patients With Peripheral Artery Disease
  392. Coronary Intravascular Ultrasound
  393. Timely PCI for STEMI — Still the Treatment of Choice
  394. Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation
  395. Adjunctive Pharmacotherapy for Thrombotic Coronary Lesions
  396. Relation of angiographic side branch calibre to myocardial mass: a proof of concept myocardial infarct index
  397. PREDICTORS OF LONG-TERM ADHERENCE TO EVIDENCE-BASED CARDIOVASCULAR DISEASE MEDICATIONS IN OUTPATIENTS WITH ATHEROTHROMBOTIC DISEASE
  398. SEVERE PULMONARY HYPERTENSION IS UNDER RECOGNIZED IN U.S. VETERAN PATIENTS
  399. FREQUENCY AND IMPACT OF PRIOR MYOCARDIAL INFARCTION AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED IN CONTEMPORARY PRACTICE: RESULTS FROM THE NCDR®
  400. GAPS IN REFERRAL TO CARDIAC REHABILITATION AFTER PCI IN THE UNITED STATES: INSIGHTS FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY
  401. Impact of Loneliness and Living Alone—Reply
  402. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial
  403. β-Blocker Use for Patients With or at Risk for Coronary Artery Disease—Reply
  404. Pushing the boundaries of renal denervation for resistant hypertension
  405. Bariatric Surgery Versus Intensive Medical Therapy in Obese Patients With Diabetes
  406. Association between obstructive sleep apnea severity and endothelial dysfunction in an increased background of cardiovascular burden
  407. Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?
  408. Novel Antiplatelet Therapies
  409. Current uses of aspirin in cardiovascular disease
  410. Cardiovascular uses and gastrointestinal complications of aspirin
  411. Conduits in Coronary Artery Bypass Grafting
  412. Predictors of Adherence to Performance Measures in Patients with Acute Myocardial Infarction
  413. Recommendations for Management of Antiplatelet Therapy in Patients Undergoing Elective Noncardiac Surgery After Coronary Stent Implantation
  414. Bariatrische chirurgie versus intensieve medicamenteuze behandeling bij diabetes met obesitas
  415. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis
  416. Cardiovascular Clinical Trials
  417. Antiplatelet therapy and proton pump inhibition
  418. Endothelial progenitor cell response to antiproliferative drug exposure
  419. β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease
  420. Percutaneous Coronary Intervention
  421. Acute Coronary Syndromes (ST Elevation and Non-ST Elevation)
  422. Introduction to Randomized Clinical Trials in Cardiovascular Disease
  423. EXAMINATION of new drug-eluting stents—top of the class!
  424. Age and Gender Differences in Quality of Care and Outcomes for Patients with ST-segment Elevation Myocardial Infarction
  425. Antiplatelet Therapy Following Myocardial Infarction in Patients With Diabetes
  426. Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents
  427. Admission Heart Rate and In-Hospital Outcomes in Patients Hospitalized for Heart Failure in Sinus Rhythm and Atrial Fibrillation
  428. Do BNP Levels and Prognostic Value Vary by Race/Ethnicity in Patients Hospitalized With Heart Failure?
  429. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review
  430. Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: A comparative study
  431. Increasing Proportion of Clinical Trials Using Noninferiority End Points
  432. Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
  433. Trends in Smoking Cessation Counseling: Experience From American Heart Association‐Get With The Guidelines
  434. Clopidogrel resistance – A clear problem with an unclear solution
  435. Atherothrombotic Disease, Traditional Risk Factors, and 4‐Year Mortality in a Latin American Population: The REACH Registry
  436. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
  437. Declining Coronary Artery Bypass-Related Mortality: More Than Meets the Eye?
  438. Fate of individuals with ischemic amputations in the REACH Registry: Three-year cardiovascular and limb-related outcomes
  439. LONG-TERM RISK AND PROGNOSIS OF RECURRENT CARDIOVASCULAR EVENTS IN THE REACH REGISTRY
  440. METABOLIC SYNDROME, DIABETES MELLITUS, OR BOTH AND CARDIOVASCULAR RISK IN OUTPATIENTS AT RISK OF OR WITH ATHEROTHROMBOSIS IN THE REACH REGISTRY
  441. RESISTANT HYPERTENSION: A FREQUENT AND OMINOUS FINDING AMONG HYPERTENSIVE PATIENTS WITH ATHEROTHROMBOSIS
  442. GENDER DIFFERENCES IN CARDIOVASCULAR RISK IN DIABETIC AND NON-DIABETIC OUTPATIENTS AT RISK OF OR WITH ATHEROTHROMBOSIS IN THE REACH REGISTRY
  443. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction
  444. ATOPAXAR AND ITS EFFECTS ON MARKERS OF PLATELET ACTIVATION AND INFLAMMATION: RESULTS FROM THE LANCELOT PROGRAM
  445. DIFFERENTIAL EFFECTS OF SMOKING ON LONG-TERM OUTCOMES IN PATIENTS WITH ATHEROSCLEROTIC VASCULAR DISEASE TREATED WITH ASPIRIN OR CLOPIDOGREL: INSIGHTS FROM THE CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS AT RISK OF ISCHEMIC EVENTS TRIAL
  446. CLINICAL OUTCOMES USING A PLATELET-FUNCTION GUIDED APPROACH FOR PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH STROKE OR TIA
  447. PREVALENCE AND OUTCOMES OF RADIAL AND FEMORAL APPROACHES TO PERCUTANEOUS CORONARY INTERVENTION. INSIGHTS FROM THE NATIONAL VETERANS AFFAIRS CLINICAL ASSESSMENT, REPORTING AND TRACKING PROGRAM
  448. Protocol for Vasoreactivity Testing With Epoprostenol in Pulmonary Hypertension
  449. LONG-TERM PATENCY OF CORONARY ARTERY BYPASS VEIN GRAFTS HARVESTED ENDOSCOPICALLY: A META-ANALYSIS
  450. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis
  451. Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction
  452. Drug-eluting versus bare-metal stents in saphenous vein graft lesions
  453. Reply to the letter by Chatterjee et al “Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial”
  454. Peripheral and Cerebrovascular Intervention
  455. Percutaneous Coronary Intervention
  456. Endovascular Treatment of Noncoronary Obstructive Vascular Disease
  457. Treatment with ω-3 fatty acids reduces serum C-reactive protein concentration
  458. Influence of metabolic syndrome on outcome after percutaneous coronary intervention
  459. Ask the Experts: Cardiovascular complications in diabetic patients
  460. Right Heart Catheterization, Coronary Angiography, and Percutaneous Coronary Intervention
  461. Peripheral and Cerebrovascular Disease
  462. Ethnic Differences in Cardiovascular Risks and Mortality in Atherothrombotic Disease: Insights From the REduction of Atherothrombosis for Continued Health (REACH) Registry
  463. Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry
  464. Improvement in use of anticoagulation therapy in patients with ischemic stroke: Results from Get With The Guidelines–Stroke
  465. Changes in Myocardial Infarction Guideline Adherence as a Function of Patient Risk
  466. Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease
  467. Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: Findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD)
  468. Accuracy and reliability of point-of-care platelet assays in hemodialysis patients
  469. The Importance of Consistent, High-Quality Acute Myocardial Infarction and Heart Failure Care
  470. Predictors of Hospital Length of Stay in Heart Failure: Findings from Get With the Guidelines
  471. Femoral Arterial Access and Closure
  472. The evolution of antiplatelet therapy in cardiovascular disease
  473. Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort
  474. Evaluation of Agents to Reduce Infarct Size
  475. Endothelial Dysfunction In Obstructive Sleep Apnea
  476. Use and Predictors of Heart Failure Disease Management Referral in Patients Hospitalized With Heart Failure: Insights From the Get With the Guidelines Program
  477. Anticoagulant Agents in Acute Coronary Syndromes
  478. Methodological Remarks Concerning the Recent Meta-analysis of Carotid Artery Stenting vs Carotid Endarterectomy—Reply
  479. CLOPIDOGREL PHARMACOKINETICS AND PHARMACODYNAMICS VARY WIDELY, INDEPENDENT OF CYP2C19 POLYMORPHISMS, DIET, SMOKING, PROTON PUMP INHIBITORS AND OTHER CO-MEDICATIONS
  480. A nonimaging catheter for measurement of coronary artery lumen area
  481. Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: A meta-analysis of randomized controlled trials
  482. Glycoprotein IIb/IIIa Inhibitors
  483. Usefulness of Postexercise Ankle-Brachial Index to Predict All-Cause Mortality
  484. Review: Antiplatelet Therapy in Acute Coronary Syndromes
  485. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG)
  486. Antiplatelet Therapy in Coronary Heart Disease Prevention
  487. Carotid Artery Stenting vs Carotid Endarterectomy
  488. Results from the Reduction of Atherothrombosis for Continued Health (REACH) Registry
  489. Two-Year Vascular Event Rates in Patients with Symptomatic Cerebrovascular Disease: The REACH Registry
  490. Antiplatelet Therapy
  491. Cardiovascular risk profiles and outcomes of Chinese living inside and outside China
  492. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG)
  493. Low-Dose Aspirin-Induced Ulceration Is Attenuated by Aspirin–Phosphatidylcholine: A Randomized Clinical Trial
  494. Clopidogrel with or without Omeprazole in Coronary Artery Disease
  495. Corrigendum to “Current strategies in antiplatelet therapy — Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?” [Pharmacol. Ther. 127(2) (2010) 95–107]
  496. Antiplatelet Therapy in Acute Coronary Syndrome (ACS) and PCI: Practical Strategies to Improve Outcomes
  497. Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment
  498. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry
  499. Secondary prevention of stroke: can we do better than aspirin?
  500. Acute coronary syndrome update for hospitalists
  501. Safety and efficacy of carotid stenting in individuals with concomitant severe carotid and aortic stenosis
  502. Safety and efficacy of carotid stenting in individuals with concomitant severe carotid and aortic stenosis
  503. Usefulness of Biomarker Strategy to Improve GRACE Score's Prediction Performance in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome and Low Event Rates
  504. Current strategies in antiplatelet therapy — Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?
  505. Use and Predictors of Heart Failure Disease Management Referral in Patients Hospitalized With Heart Failure: Insights from the American Heart Association – Get with the Guidelines Program
  506. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry
  507. Faculty of 1000 evaluation for Population trends in the incidence and outcomes of acute myocardial infarction.
  508. Assessment of Atherothrombosis and Its Treatment in Mexico: First‐Year Data of the REACH Registry
  509. The psychological impact of learning about APOE-cardiovascular disease associations during genetic risk assessment for Alzheimer's disease: Findings from the reveal study
  510. Advancing the Care of Cardiac Patients Using Registry Data
  511. The State of Periprocedural Antiplatelet Therapy After Recent Trials
  512. Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence
  513. Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective
  514. Faculty of 1000 evaluation for Revascularization versus medical therapy for renal-artery stenosis.
  515. T1143 Reduction of Gastroduodenal Ulceration With Aspirin-Phosphatidylcholine Complex Versus Aspirin—Potential Importance of Local Mucosal Injury
  516. Platelet aspirin resistance in ED patients with suspected acute coronary syndrome
  517. Predictors of Annual Pharmaceutical Costs in Australia for Community-Based Individuals with, or at Risk of, Cardiovascular Disease
  518. Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients
  519. Bariatric surgery vs. advanced practice medical management in the treatment of type 2 diabetes mellitus: rationale and design of the Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently trial (STAMPEDE)
  520. Ethnic differences in the relationships of anthropometric measures to metabolic risk factors in Asian patients at risk of atherothrombosis
  521. Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
  522. Antiplatelet Agents in Acute Coronary Syndromes
  523. CLOPIDOGREL AND ASPIRIN VERSUS ASPIRIN ALONE IN HIGH-RISK PATIENTS WITH ESTABLISHED VASCULAR DISEASE; A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
  524. NEW OR PRESUMED NEW LEFT BUNDLE BRANCH BLOCK IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: FINDINGS FROM ACTION REGISTRY-GWTG
  525. COMPARISON OF HOSPITAL PERFORMANCE OF ACUTE MYOCARDIAL INFARCTION AND HEART FAILURE QUALITY MEASURES: FINDINGS FROM THE GET WITH THE GUIDELINES REGISTRY
  526. The economic implications of treating atherothrombotic disease in australia, from the government perspective
  527. 014 Risk score to predict serious bleeding in stable outpatients with atherothrombosis
  528. 015 The CHADS2 score predicts more accurately adverse cardiovascular outcome in atherothrombotic patients without atrial fibrillation than established scores: Insights from the European REACH registry
  529. Cardiovascular Emergencies
  530. Antiplatelet therapy: Ticagrelor in ACS—what does PLATO teach us?
  531. The Relative Efficacy and Safety of Clopidogrel in Women and Men
  532. Patient Characteristics Associated With the Choice of Triple Antithrombotic Therapy in Acute Coronary Syndromes
  533. Drug-eluting versus bare-metal stents for treating saphenous vein grafts
  534. Management of patients with aspirin and clopidogrel impaired response
  535. Prasugrel in Clinical Practice
  536. Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial
  537. Hypercholesterolemia Paradox in Relation to Mortality in Acute Coronary Syndrome
  538. Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction
  539. Tailoring Antiplatelet Therapy Based on Pharmacogenomics
  540. Drug Treatment and Cost of Cardiovascular Disease in Australia
  541. Relation of Porphyria to Atrial Fibrillation
  542. Renal function, atherothrombosis extent, and outcomes in high-risk patients
  543. Refining the role of antiplatelet therapy for atrial fibrillation
  544. Drug-eluting stent fracture and acute coronary syndrome
  545. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease
  546. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial
  547. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry
  548. Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up
  549. Response to “Atrial fibrillation and atherothrombosis: The importance of anticoagulation” by Escobar C and Barrios V
  550. Getting real with drug-eluting stents: 5-year follow up of a real-world cohort
  551. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study
  552. Impact of Drug-Eluting Versus Bare-Metal Stents on Mortality in Patients With Anemia
  553. The pain and the gain of treating patients with acute coronary syndromes—can the two be separated?
  554. Advances in Antiplatelet Therapy: Agents in Clinical Development
  555. Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease
  556. Faculty of 1000 evaluation for Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.
  557. Acute Coronary Syndromes in Clinical Practice
  558. Acute Pericarditis: Appendicitis of the Heart?
  559. Patient Selection for Carotid Stenting
  560. Bare metal stent thrombosis 13 years after implantation
  561. Regionalization of Care for ST-Segment Elevation Myocardial Infarction: Is It Too Soon?
  562. Resisting the Temptation to Oversimplify Antiplatelet Resistance⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the Americ...
  563. Definition, epidemiology, and prognosis
  564. Pathophysiology
  565. Clinical manifestations
  566. Risk stratification
  567. Anti-platelet therapies
  568. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease
  569. Prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention
  570. Anti-thrombin therapy
  571. Miscellaneous therapies
  572. Revascularization and reperfusion therapy
  573. Controversies and future approaches
  574. What Makes Platelets Angry
  575. Faculty of 1000 evaluation for Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
  576. Clopidogrel and coronary stents: Risks and benefits
  577. The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale
  578. Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents
  579. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis
  580. Comparison of Drug-Eluting Stents Versus Bare-Metal Stents for Treating ST-Segment Elevation Myocardial Infarction
  581. Introduction
  582. Anti-Inflammatory Agents and Antioxidants as a Possible “Third Great Wave” in Cardiovascular Secondary Prevention
  583. Cangrelor
  584. Faculty of 1000 evaluation for Treatment of hypertension in patients 80 years of age or older.
  585. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: Insights from randomized clinical trials
  586. Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?
  587. Aspirin and Platelet Adenosine Diphosphate Receptor Antagonists in Acute Coronary Syndromes and Percutaneous Coronary Intervention
  588. Meta-Analysis Comparing Reported Frequency of Atrial Fibrillation After Acute Coronary Syndromes in Asians Versus Whites
  589. Treating patients with non-STEMI: Stent the culprit artery only or address all lesions?
  590. Culprit-only or multivessel revascularization in patients with acute coronary syndromes
  591. Platelets in Cardiovascular Disease
  592. Managing Acute Coronary Syndromes in Clinical Practice
  593. Platelets in Cardiovascular Disease
  594. Pathophysiology
  595. Clinical manifestations
  596. Risk stratification
  597. Anti-platelet therapies
  598. Anti-thrombin therapy
  599. Miscellaneous therapies
  600. Controversies and future approaches
  601. Revascularization and reperfusion therapy
  602. Definition, epidemiology, and prognosis
  603. Percutaneous coronary intervention in nonagenarians: Age before beauty?
  604. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Stroke in Patients with a History of Atrial Fibrillation: Subgroup Analysis of the CHARISMA Randomized Trial
  605. The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention
  606. Antiplatelet Therapy and Platelet Function Testing
  607. Antiplatelet Therapy and Platelet Function Testing
  608. Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches
  609. Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes
  610. Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
  611. Assessing the Current Role of Platelet Function Testing
  612. The Optimal Treatment of Carotid Atherosclerosis: A 2008 Update and Literature Review
  613. Faculty of 1000 evaluation for Prasugrel versus clopidogrel in patients with acute coronary syndromes.
  614. Intensifying Platelet Inhibition — Navigating between Scylla and Charybdis
  615. Reply
  616. Presence of Carotid and Peripheral Arterial Disease in Patients With Left Main Disease
  617. Meta-Analysis of the Role of Statin Therapy in Reducing Myocardial Infarction Following Elective Percutaneous Coronary Intervention
  618. Clopidogrel and risk for acute coronary events
  619. Faculty of 1000 evaluation for Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial.
  620. Designing the ideal risk model for acute coronary syndromes—is simple better than complex?
  621. Anticoagulation and Antiplatelet Agents
  622. Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial
  623. Drug-Eluting Stents: Can We Move Beyond Stent Thrombosis?
  624. Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry)
  625. Acute myocardial infarction and drug-eluting stents: A green light for their use or time for measured restraint?
  626. Elevated Serum Cardiac Markers Predict Coronary Artery Disease in Patients With a History of Heart Failure Who Present With Chest Pain: Insights From the i*trACS Registry
  627. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis
  628. Bhatt response to the letter to the editor by Michaels
  629. Myocardial Infarction Secondary to a Coronary Ostial Thrombus in Antiphospholipid Syndrome
  630. Development of Coronary Aneurysm after Drug-Eluting Stent Implantation
  631. Faculty of 1000 evaluation for Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
  632. Prevalence, Awareness and Treatment of Cardiovascular Risk Factors in Patients at High Risk of Atherothrombosis in Japan
  633. Experimental Antiplatelet Therapy
  634. Evolution of Anticoagulant and Antiplatelet Therapy: Benefits and Risks of Contemporary Pharmacologic Agents and Their Implications for Myonecrosis and Bleeding in Percutaneous Coronary Intervention
  635. Long-Term Benefit of Statin Therapy Initiated??during Hospitalization for??an??Acute??Coronary Syndrome
  636. Incremental Effect of Clopidogrel on Important??Outcomes in Patients with Cardiovascular Disease
  637. Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents: A retrospective cohort study
  638. Introduction
  639. Walk This Way: Early Ambulation After Cardiac Catheterization—Good for the Patient and the Health Care System
  640. Identification of and Management Approaches for the High-Risk Patient
  641. Clinical Trials Update from the Annual Scientific Session of the American College of Cardiology 2006
  642. Late Thrombosis of Drug-Eluting Stents: A Meta-Analysis of Randomized Clinical Trials
  643. Response to Letter to the Editor
  644. Anticoagulation and Antiplatelet Agents
  645. Benefit of Early Invasive Therapy in Acute Coronary Syndromes
  646. Use of Platelet Glycoprotein IIb/IIIa Inhibitors in Saphenous Vein Graft Percutaneous Coronary Intervention and Clinical Outcomes
  647. Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?
  648. Interpreting observational studies—look before you leap
  649. Paradoxical Rebound Platelet Activation After Painkillers Cessation: Missing Risk for Vascular Events?
  650. Faculty of 1000 evaluation for Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.
  651. Clinical Outcomes in Metabolic Syndrome
  652. Bare metal stent restenosis is not a benign clinical entity
  653. Faculty of 1000 evaluation for Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
  654. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers
  655. Antithrombotic Therapy for Percutaneous Coronary Intervention
  656. Clopidogrel to Treat Patients With Non–ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge
  657. Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?
  658. Usefulness of an Elevated Neutrophil to Lymphocyte Ratio in Predicting Long-Term Mortality After Percutaneous Coronary Intervention
  659. CHARISMA
  660. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  661. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial
  662. Clopidogrel Bisulfate In ST-Segment Elevation Myocardial Infarction
  663. Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention
  664. The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention
  665. Faculty of 1000 evaluation for Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
  666. Systemic Complications of Endovascular Therapy
  667. Chronic Obstructive Pulmonary Disease as a Predictor of Mortality in Patients Undergoing Percutaneous Coronary Intervention
  668. Outcomes in African Americans and whites after percutaneous coronary intervention
  669. Fibrinolytic therapy in peripheral arterial disease
  670. To Cath or Not to Cath
  671. The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin—Reply
  672. Acute coronary syndrome statistics: What you don't see can hurt you
  673. Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling
  674. Risk of Thrombosis With the Use of Sirolimus-Eluting Stents for Percutaneous Coronary Intervention (from Registry and Clinical Trial Data)
  675. Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials
  676. Plaque regression—A new target for antiatherosclerotic therapy
  677. Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting
  678. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center
  679. Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting
  680. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?
  681. Atherothrombosis and Stroke – A Lot More to Know!
  682. Thrombin, an ideal target for pharmacological inhibition: A review of direct thrombin inhibitors
  683. Introduction
  684. Antiplatelet Agents in Patients Undergoing Percutaneous Coronary Intervention
  685. Renal failure after percutaneous coronary intervention is associated with high mortality
  686. Variability in platelet responsiveness to clopidogrel among 544 individuals
  687. Symptomatic patients have similar outcomes compared with asymptomatic patients after carotid artery stenting with emboli protection
  688. GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention
  689. Impact of female sex on outcome after percutaneous coronary intervention
  690. Who Is Best Trained to Treat Peripheral Arterial Disease?–Reply–I
  691. Controversies of Oral Antiplatelet Therapy in Acute Coronary Syndromes and Percutaneous Coronary Intervention
  692. Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations
  693. Coronary Artery Inflammation
  694. Embolization As a Pathological Mechanism
  695. Effect of chronic kidney disease on outcomes after carotid artery stenting
  696. Peripheral Arterial Disease in the Catheterization Laboratory: An Underdetected and Undertreated Risk Factor
  697. Peripheral Arterial Disease in the Catheterization Laboratory: An Underdetected and Undertreated Risk Factor
  698. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  699. Percutaneous Coronary Intervention in Diabetics
  700. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention
  701. Management of Acute Coronary Syndrome in Diabetes Mellitus
  702. The yin and yang of arterial inflammation**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
  703. Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality
  704. Inflammation and restenosis: is there a link?
  705. Current use of antiplatelet agents
  706. Intracranial hemorrhage and hyperperfusion syndrome following carotid artery stenting
  707. Severe bilateral carotid stenosis
  708. Inflammation and atherosclerosis
  709. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention
  710. 1043-41 Baseline heart rate predicts all-cause mortality after percutaneous coronary intervention
  711. 1080-43 Successful percutaneous revascularization of chronic total occlusions is associated with a significant survival benefit in nondiabetics
  712. Aspirin resistance: more than just a laboratory curiosity**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
  713. Aspirin dose and six-month outcome after an acute coronary syndrome
  714. 1156-63 Inaccuracy of Doppler ultrasonography for assessing restenosis after internal carotid artery stenting
  715. 877-6 Symptomatic patients have similar outcomes compared to asymptomatic patients after carotid artery stenting with emboli protection
  716. 1135-69 Impact of gender on outcome following percutaneous coronary intervention
  717. 1081-52 Prediction of death or myocardial infarction by exercise SPECT scintigraphy among patients who have had recent coronary stenting
  718. 1100-59 High-dose clopidogrel loading rapidly reduces both platelet inflammatory marker expression and aggregation
  719. 1120-65 Emboli protection improves thrombolysis in myocardial infarction perfusion score in saphenous vein graft intervention
  720. The Efficacy and Safety of Perioperative Antiplatelet Therapy
  721. Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers
  722. An international prospective observational registry in subjects at risk of atherothrombotic events
  723. Feasibility of simultaneous bilateral carotid artery stenting
  724. Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation
  725. Red vs White Thrombi: Treating the Right Clot Is Crucial—Reply
  726. Cost-effectiveness of Newer Antiplatelet Drugs—Reply
  727. Advances in antiplatelet therapy
  728. Preprocedural white blood cell count and death after percutaneous coronary intervention
  729. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials
  730. Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes
  731. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes
  732. Aspirin and Clopidogrel in Acute Coronary Syndromes
  733. Highlights of the 2002 Update to the 2000 American College of Cardiology/American Heart Association Acute Coronary Syndrome Guidelines
  734. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: To what extent should the results be generalizable?
  735. Clopidogrel pretreatment prior to percutaneous coronary intervention attenuates periprocedural rise of C-reactive protein
  736. Clopidogrel pretreatment reduces platelet inflammatory marker expression in patients undergoing percutaneous coronary intervention
  737. Marked survival benefit associated with statin pretreatment prior to percutaneous coronary intervention is dependent upon the preprocedural inflammatory status
  738. Relation of insurance status to performance of coronary angiography in patients with unstable angina pectoris or acute myocardial infarction
  739. Renal insufficiency in the setting of an acute coronary syndrome is associated with a marked increase in death and myocardial infarction at 30 days
  740. Impact of the prediabetic state on long-term outcomes following percutaneous coronary intervention
  741. Comparison of the safety and efficacy of the use of emboli protection device versus glycoprotein IIb/IIIa inhibitor during carotid stenting
  742. Hydration versus N-acetylcysteine for protection of renal function in patients with renal insufficiency undergoing percutaneous coronary intervention
  743. An invasive strategy is associated with decreased mortality in patients with unstable angina and non–ST-elevation myocardial infarction: GUSTO IIb trial
  744. Scientific and therapeutic advances in antiplatelet therapy
  745. Advances in antiplatelet therapy
  746. Carotid brachytherapy for in-stent restenosis
  747. Percutaneous Treatment for Pacemaker-Associated Superior Vena Cava Syndrome
  748. Abciximab
  749. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus
  750. Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention
  751. Need to Test the Arterial Inflammation Hypothesis
  752. Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study)
  753. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency
  754. Successful “pre-closure” of 7Fr and 8Fr femoral arteriotomies with a 6Fr suture-based device (the Multicenter Interventional Closer Registry)
  755. Dramatic increase in 30-day mortality in diabetic patients with non-ST segment elevation acute coronary syndromes
  756. Percutaneous treatment for pacemaker lead-related SVC syndrome
  757. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention
  758. Reduction in percutaneous coronary intervention-related bleeding with bivalirudin is particularly striking in women
  759. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction
  760. Renal artery end-diastolic velocity and renal artery resistance index as predictors of outcome after renal stenting
  761. Effect of Clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein
  762. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization
  763. ANTIPLATELET AND ANTICOAGULANT THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC HEART DISEASE
  764. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT
  765. Striking prognostic significance of elevated CRP in renal impairment patients undergoing PCI Mark A. Robbins, Derek P. Chew, Deepak L. Bhatt, Abdulhay Albirini, Leslie S. Cho, Jakob Schneider, Stephen G. Ellis, Eric J. Topol. Cleveland Clinic Foundatio...
  766. Is simultaneous bilateral carotid artery stenting safe? Deepak L. Bhatt, Debabrata Mukherjee, Marco Roffi, Samir R. Kapadia, Khaled M. Ziada, Derek P. Chew, Jay S. Yadav. Cleveland Clinic Foundation, Cleveland, OH
  767. CRP provides prognostic value in addition to ACC/AHA lesion score following PCI Derek P. Chew, Mark A. Robbins, Deepak L. Bhatt, Debabrata Mukherjee, Marco Roffi, Eric J. Topol, Stephen G. Ellis. Cleveland Clinic Foundation, Cleveland, OH
  768. Percutaneous interventions fo coronary bypass grafts have doubled major adverse events Marco Roffi, Debabarata Mukherjee, Deepak L. Bhatt, Derek P. Chew, Khaled M. Ziada, Danielle M. Prosper, Stephen G. Ellis, Eric J. Topol. Cleveland Clinic Foundation...
  769. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease
  770. Oral Glycoprotein IIb/IIIa Inhibitors
  771. Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
  772. Optimizing Percutaneous Coronary Revascularization in Diabetic Women: Analysis from the EPISTENT Trial
  773. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin
  774. The benefit of abciximab in percutaneous coronary revascularization is not device-specific
  775. Abciximab reduces mortality in diabetics following percutaneous coronary intervention
  776. Percutaneous coronary intervention for patients with prior bypass surgery: therapy in evolution
  777. ANTIPLATELET AND ANTICOAGULANT THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC HEART DISEASE
  778. Update on Clinical Trials of Antiplatelet Therapy for Cerebrovascular Diseases
  779. Corrected TIMI frame count does not predict 30-day adverse outcomes after reperfusion therapy for acute myocardial infarction
  780. Direct myocardial revascularization and angiogenesis—how many patients might be eligible?
  781. Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention
  782. Rhabdomyolysis Due to Pulsed Electric Fields
  783. Role of cell membrane rupture in the pathogenesis of electrical trauma
  784. Indications for Carotid Artery Stenting
  785. Clopidogrel: How Much, How Soon, and How Long
  786. Antiplatelet Therapy in Chronic Coronary Artery Disease
  787. Pathophysiological and pharmacological treatment of thromboembolic and ischemic complications associated with endovascular procedures
  788. Skeletal muscle cell membrane electrical breakdown in electrical trauma